Havana, May 30 (Prensa Latina) The Cuban Biotechnological and Pharmaceutical Industries Group (BioCubaFarma) is advancing today a strategy aimed at the production of 525 medicines in the midst of the limitations imposed by the U.S. economic blockade.
“The sector is working tirelessly to guarantee 525 of the 849 medicines included in the basic list of the National Health System,” said BioCubaFarma’s president, Eduardo Martinez.
This effort – Granma newspaper reported – is being carried out in the midst of limitations in the availability of raw materials, derived from the intensification of the economic, commercial and financial blockade imposed by the United States against Cuba.
The National Medicines Program’s premise is to ensure the availability of medicines for the health of our people, as well as the development and introduction of innovative products and technologies that allow for an increase in exports.
This scheme was conceived on five pillars: the substitution of imports; the strengthening of the Biopharmaceutical Industry; the application of the Natural and Traditional Medicine program, and the development of pharmaceutical services and Pharmacoepidemiology.